Abstract
Drug treatment optimization in primary open-angle glaucoma (POAG) is a topical issue of ophthalmology in recent decades. The review focuses on the choice of local hypotensive therapy and the effectiveness of a fixed combination (FC) of dorzolamide / timolol in glaucoma treatment. Since decreased perfusion eye pressure and disturbed regulation of local hemodynamics affect the development and progression of glaucomatous optical neuropathy, the use of anti-glaucomatous drugs or other hypotensive agents requires taking account of their effect on intraocular pressure (IOP), visual functions, and ocular blood flow. Most studies show that the hypotensive and hemodynamic effects of dorzolamide/timolol FC contribute to the preservation of visual fields in POAG patients by reducing significant risk factors for POAG progression, such as increased IOP and blood flow deficiency in the retinal and choroidal vessels. Improved hemodynamic parametersdue to local hypotensive treatment can be considered as basis for visual function stabilization, especially in long-term chronic courses of the disease.
Highlights
Drug treatment optimization in primary open-angle glaucoma (POAG) is a topical issue of ophthalmology in recent decades
The review focuses on the choice of local hypotensive therapy and the effectiveness of a fixed combination (FC) of dorzolamide / timolol in glaucoma treatment
Improved hemodynamic parameters due to local hypotensive treatment can be considered as basis for visual function stabilization, especially in long-term chronic courses of the disease
Summary
Drug treatment optimization in primary open-angle glaucoma (POAG) is a topical issue of ophthalmology in recent decades. [59] при изучении эффективности и переносимости терапии ФК дорзоламид/тимолол (рН = 5,6), бринзоламид/тимолол (рН = 7,2) установили, что, несмотря на разницу в рН препаратов группы ИКА и ожидаемую вследствие этого худшую переносимость дорзоламида, частота клинического успеха (достижение целевого ВГД и отсутствие дискомфорта) в группе бринзоламид/тимолол составила 86,5 % (32 из 37 пациентов) по сравнению с 94,4 % (34 из 36 пациентов) в группе дорзоламид/тимолол (p < 0,001).
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have